A glucagon-like peptide-1 injection mimics a gut hormone to lower blood sugar and curb appetite. Learn how GLP-1 drugs work, who qualifies, and side effects.
A glucagon-like peptide-1 injection is a prescription medication that copies a hormone your gut releases after you eat. It lowers blood sugar, slows stomach emptying, and reduces appetite. In the United States, these injections are FDA-approved for type 2 diabetes, chronic weight management, or both, depending on the specific drug.
They are not a cure for diabetes or obesity, and they are not sold over the counter. A healthcare professional decides whether an injectable GLP-1 medication fits your health history.
Common examples include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda).
What Is Glucagon-Like Peptide-1?
Glucagon-like peptide-1 is a hormone made by L-cells in the small intestine. It belongs to a family of hormones called incretins, which help the body handle glucose after a meal. Natural GLP-1 is broken down within a few minutes by the enzyme DPP-4.
Prescription injections solve that problem with modified molecules that resist rapid breakdown. The result is a steady, active level of the hormone's effects that can last for days.
If you have ever wondered what does glucagon-like peptide 1 do, the answer starts in the gut and ends in the pancreas and brain. The injected form simply amplifies that same natural signal.
How GLP-1 Injections Work in the Body
Every prescription GLP-1 injection binds to the same target, which is why these medications are described as a glucagon-like peptide-1 receptor agonist.
- Pancreas: increases insulin release when glucose is high and suppresses glucagon.
- Stomach: slows gastric emptying so food digests more gradually.
- Brain: signals fullness and lowers appetite.
Because the insulin effect depends on blood sugar levels, GLP-1 injections rarely cause hypoglycemia when used alone. The risk rises when they are combined with insulin or sulfonylureas.
FDA-Approved GLP-1 Injection Options
Several glucagon-like peptide-1 drugs are available by prescription in the US. Most are given as a subcutaneous injection into the abdomen, thigh, or upper arm, and dosing ranges from twice daily to once weekly. Whether a product is written as glucagon-like peptide-1 injection or glucagon like peptide 1 injection, it refers to the same class of prescription medicine.
| Generic name | Common brand names | Typical dosing | FDA-approved uses |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | Once weekly injection | Type 2 diabetes; chronic weight management (Wegovy) |
| Liraglutide | Victoza, Saxenda | Once daily injection | Type 2 diabetes; chronic weight management (Saxenda) |
| Dulaglutide | Trulicity | Once weekly injection | Type 2 diabetes |
| Exenatide | Byetta, Bydureon | Twice daily or once weekly | Type 2 diabetes |
| Tirzepatide | Mounjaro, Zepbound | Once weekly injection | Type 2 diabetes; chronic weight management (Zepbound) |
Tirzepatide is a dual GIP and GLP-1 agonist rather than a pure GLP-1 medication, but it is usually discussed alongside this class. Exenatide and liraglutide are older options that require more frequent dosing.
GLP-1 Injections for Weight Loss
Semaglutide and liraglutide are FDA-approved for chronic weight management under specific brand names. Research on glucagon-like peptide-1 weight loss shows average reductions of roughly 10% to 20% of body weight over a year or more, depending on the drug and dose.
Typical eligibility is a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure or type 2 diabetes. Medication works alongside nutrition and physical activity, not instead of them.
Weight often returns after the medication is stopped, so many patients and clinicians plan for long-term treatment.
Side Effects and Safety
Most glucagon-like peptide-1 side effects are digestive and mild. Nausea, vomiting, diarrhea, constipation, and stomach discomfort are the most frequently reported problems, and they usually ease after the first few weeks or after a dose increase.
Serious but uncommon risks include pancreatitis, gallbladder disease, bowel obstruction, and kidney injury from dehydration. The FDA requires a boxed warning about thyroid C-cell tumors seen in rodents, and these drugs are not recommended for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome.
Seek medical attention for severe abdominal pain, persistent vomiting, or signs of dehydration. Anyone using an injectable GLP-1 medication should review symptoms with a healthcare professional instead of adjusting the dose alone.
Prescription Injections vs. GLP-1 Supplements
Products sold as a glucagon-like peptide-1 supplement are not the same thing as prescription injections. Most contain fiber, berberine, or herbal extracts and no actual incretin drug.
No over-the-counter GLP-1 pill or supplement is FDA-approved for weight loss or diabetes. Unregulated peptides purchased online have unknown purity and dosing, which makes them a genuine safety concern.
Questions to Ask Your Clinician
Before starting treatment, ask how the dose will be increased over time and what to do about a missed injection. A few practical questions help:
- How should the medication be stored, and does it need refrigeration?
- What is the out-of-pocket cost, and does my insurance require prior authorization?
- Are there oral or alternative options that fit my health profile?
- Which symptoms should prompt a phone call rather than a wait-and-see approach?
GLP-1 injections are effective tools for many people, but they are prescription medicines with real risks. Results vary from person to person, and ongoing medical supervision is part of safe use.
Frequently Asked Questions
Is a glucagon-like peptide-1 injection the same as Ozempic?
Ozempic is one brand of semaglutide, which is a single glucagon-like peptide-1 injection product. Other GLP-1 injections include Trulicity (dulaglutide), Victoza (liraglutide), and Byetta (exenatide), and each has its own dosing schedule and approved uses. They work on the same receptor but are not interchangeable without a clinician's guidance.
How much weight can you lose with a GLP-1 injection?
In clinical trials, semaglutide 2.4 mg produced average weight loss of about 15% of body weight over 68 weeks, while liraglutide 3.0 mg produced roughly 8%. Individual results vary widely based on dose, treatment duration, diet, and activity level. These medications are intended for people who meet specific BMI criteria.
What happens if you stop taking GLP-1 injections?
Appetite typically returns, and much of the lost weight often comes back within months unless eating and activity habits are maintained. In type 2 diabetes, blood sugar can rise again after the medication is stopped. Anyone considering stopping should talk with their prescriber first rather than quitting abruptly.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.